AlphAIalphai — Financial news for AI agents
The Manila TimesAPR 162 min read$ARQT

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Arcutis Biotherapeutics, Inc. announced it will report its first quarter 2026 financial results and provide a business update on May 6, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast the same day at 4:30 PM ET, with a replay available on its investor website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a growing portfolio for inflammatory skin diseases.

Original reporting
The Manila Times · GlobeNewswire
Published Apr 16, 2026, 12:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 16, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
alphai data visualization · based on The Manila Times
Decision brief

The 30-second read

$ARQTNeutralMed
01

Why it matters

The scheduled earnings release and conference call are key events that could influence the company's stock performance in the short term.

02

Market read

High relevance for biotech investors and traders interested in company-specific catalysts.

03

What to watch

Market reaction may be influenced by broader biotech sector trends or macroeconomic factors unrelated to earnings.

Timing: High, as the earnings report is scheduled for May 6, 2026.

Background

Arcutis is a biopharmaceutical company specializing in immuno-dermatology, with a focus on inflammatory skin diseases.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

The news pertains directly to Arcutis Biotherapeutics, Inc., a company focused on immuno-dermatology, which is relevant to the life sciences sector.

Expected impact

Potential short-term volatility around the earnings date; no clear directional bias expected without actual results.

Evidence & confidence

Earnings reports typically cause volatility; however, without preliminary data or analyst estimates, the impact remains uncertain.

Market effects

Sector

Positive developments in immuno-dermatology could benefit biotech and pharmaceutical stocks within the life sciences sector.

Regional

Primarily US-focused, with potential influence on related regional markets depending on results.

Global

Limited; company-specific news with minimal immediate global market impact.

Counterpoint

What could challenge this read

If earnings disappoint, ARQT could experience significant declines, presenting short-selling opportunities.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    A clinical-stage biopharmaceutical company focused on immuno-dermatology.

Read at source← All news

Related articles

AUG 5
$ARQTHigh

Arcutis Biotherapeutics, Inc. (ARQT): Results of Operations and Financial Condition

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressreleaseex991q22026.htm EX-99.1 Document Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% ve

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min